Q2 2019 |
23 |
$120M |
+$76.3M |
-$1.73M |
+$74.5M |
ICPT, INSM, BOLD, NBIX, SRPT
|
13F-HR |
8/14/2019, 04:08 PM |
Q1 2019 |
24 |
$82.4M |
+$23.7M |
-$122M |
-$98.2M |
BOLD, HRTX, INSM, IMMU, BHC
|
13F-HR |
5/15/2019, 04:06 PM |
Q4 2018 |
23 |
$243M |
+$102M |
-$91M |
+$11.3M |
XBI, BMRN, NVS, TEVA, HRTX
|
13F-HR |
2/14/2019, 03:00 PM |
Q3 2018 |
56 |
$522M |
+$162M |
-$142M |
+$20.1M |
XBI, EXEL, AGN, IMMU, BMRN
|
13F-HR |
11/14/2018, 03:06 PM |
Q2 2018 |
45 |
$646M |
+$182M |
-$44.5M |
+$138M |
XBI, AGN, IMMU, EXEL, BMRN
|
13F-HR |
8/14/2018, 04:09 PM |
Q1 2018 |
40 |
$607M |
+$234M |
-$16M |
+$218M |
XBI, AGN, BMY, BMRN, SHPG
|
13F-HR |
5/15/2018, 04:17 PM |
Q4 2017 |
39 |
$542M |
+$307M |
-$8.23M |
+$299M |
XBI, AGN, SHPG, MYL, MRK
|
13F-HR |
2/14/2018, 05:08 PM |
Q3 2017 |
38 |
$389M |
+$278M |
-$22.5M |
+$256M |
XBI, SGENXXXX, TEVA, CLVSQ, GSKXXXX
|
13F-HR |
11/14/2017, 03:20 PM |
Q2 2017 |
41 |
$230M |
+$83.1M |
-$25.5M |
+$57.6M |
SHPG, AZN, ALXN, GSKXXXX, CELG
|
13F-HR |
8/14/2017, 04:40 PM |
Q1 2017 |
36 |
$196M |
+$115M |
-$13.6M |
+$101M |
PFE, SHPG, AZN, CELG, GSKXXXX
|
13F-HR |
5/15/2017, 04:37 PM |
Q4 2016 |
39 |
$171M |
+$113M |
-$17.2M |
+$95.4M |
SHPG, NVS, CELG, ALXN, PFE
|
13F-HR |
2/14/2017, 04:00 PM |
Q3 2016 |
33 |
$163M |
+$76.9M |
-$15.9M |
+$61M |
PFE, GSKXXXX, SHPG, XLRN, SGENXXXX
|
13F-HR |
11/14/2016, 03:08 PM |
Q2 2016 |
35 |
$115M |
+$62.3M |
-$834K |
+$61.5M |
PFE, GSKXXXX, SHPG, SGENXXXX, MYL
|
13F-HR |
8/15/2016, 04:24 PM |
Q1 2016 |
32 |
$96.5M |
+$56.2M |
-$2.94M |
+$53.2M |
CELG, SHPG, PFE, AGN, BMY
|
13F-HR |
5/13/2016, 11:33 AM |
Q4 2015 |
45 |
$70.5M |
|
|
|
PFE, BMY, CELG, MRK, SGENXXXX
|
13F-HR |
2/16/2016, 09:25 AM |